Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T20:48:30.955Z.
Calculation as of: 2026-10-06T20:48:30.955Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8f998ac52bf92492c18c8c1a056427339c5b213780e3da80cf9ae2163b61907c
PE RATIO
N/A
Market Cap
$259.56M
PE Ratio
N/A
TTM Avg
16.07
3Y Avg
13.93
5Y Avg
35.67
Market Cap
$259.12M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$262.92M
PE Ratio
N/A
TTM Avg
175.46
3Y Avg
175.46
5Y Avg
175.46
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Treace Medical Concepts, Inc. (TMCI) | $259.49M | N/A | N/A | N/A | N/A |
| OraSure Technologies, Inc. (OSUR)vs › | $259.56M | N/A | 16.07 | 13.93 | 35.67 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.14M | N/A | N/A | N/A | N/A |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $259.12M | N/A | N/A | N/A | N/A |
| Palisade Bio, Inc. (PALI)vs › | $258.63M | N/A | 4.44 | 4.44 | 4.44 |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $261.27M | N/A | 4.20 | 4.20 | 4.20 |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $261.43M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $256.47M | N/A | 14.47 | 14.47 | 17.60 |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $262.92M | N/A | 175.46 | 175.46 | 175.46 |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.88M | N/A | 83.73 | 30.92 | 28.56 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$4.00
Forward EPS (Est.)
$-0.85
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
